HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating for Milestone Pharmaceuticals (NASDAQ:MIST) and maintained a $25 price target.
October 14, 2024 | 10:19 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Milestone Pharmaceuticals, maintaining a $25 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $25 price target by a reputable analyst firm like HC Wainwright & Co. suggests positive sentiment and confidence in Milestone Pharmaceuticals' future performance. This is likely to have a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100